Allan JN et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: A polled analysis from four clinical trials. Br J Haematol 2022;196(4):947-53. Abstract
Allan JN et al. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica 2022;107(4):984-7. Abstract
Al-Sawaf O et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: Extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol 2021;39(36):4049-60. Abstract
Al-Sawaf O et al. Should undetectable minimal residual disease be the goal of chronic lymphocytic leukemia therapy? Hematol Oncol Clin N Am 2021;35(4):775-91. Abstract
Bar-Or A et al. Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis. CNS Drugs 2021;35(9):985-97. Abstract
Brem EA, O’Brien S. Frontline management of CLL in 2021. JCO Oncol Pract 2022;18(2):109-13. Abstract
Brem EA, O’Brien S. Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis. Blood Adv 2022;6(4):1361-4. Abstract
Byrd JC et al. Acalabrutinib versus ibrutinib in preciously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract
Eichhorst B et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: First co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial. ASH 2021;Abstract 71.
Furman RR et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia 2021;35(11):3201-11. Abstract
Ghia P et al. First-line treatment with ibrutinib (ibr) plus venetoclax (ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the phase 2 Captivate study. ASH 2021;Abstract 68.
Ghia P et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. ASCO 2021;Abstract 7051.
Hillmen P et al. First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract LBA1900.
Hillmen P et al. Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: Results of the phase III NCRI FLAIR trial. ASH 2021;Abstract 642.
Jacobs R et al. Efficacy and safety of ublituximab in combination with umbralisib (U2) in patients with chronic lymphocytic leukemia (CLL) by treatment status: A sub-analysis of the phase 3 Unity-CLL study. ASH 2021;Abstract 3726.
Jain N et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 2021;35(12):3421-9. Abstract
Kater A et al. Fixed-duration ibrutinib and venetoclax (i + v) versus chlorambucil plus obinutuzumab (clb + o) for first-line (1L) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 GLOW study. EHA 2021;Abstract LB1902.
Ma S et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. Blood 2021;138(10):836-46. Abstract
Mato AR et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. ASH 2021;Abstract 391.
Mato AR et al. Recognizing unmet need in the era of targeted therapy for CLL/SLL: “What’s past is prologue” (Shakespeare). Clin Cancer Res 2022;28(4):603-8. Abstract
Melenhorst JJ et al. Decade-long leukaemia remissions with persistence of CD4 + CAR T cells. Nature 2022;602(76897):503-9. Abstract
Munir T et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: The GLOW study. ASH 2021;Abstract 70.
Niemann CU et al. Time-limited venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have undetectable minimal residual disease (uMRD) – Primary analysis from the randomized phase 2 VISION JO141 trial. ASH 2021;Abstract 69.
O’Brien SM et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol 2021;11:720704. Abstract
Shanafelt TD et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial. Blood 2022;[Online ahead of print]. Abstract
Sharman JP et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia 2022;36(4):1171-5. Abstract
Sharman JP et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): A phase 3, multicentre, open-label, randomised trial. Lancet Haematol 2021;8(4):e254-66. Abstract
Siddiqi T et al. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: Pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Lymphoma 2022;[Online ahead of print]. Abstract
Siddiqi T et al. Phase 1 TRANSCENT CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2022;139(12):1794-806. Abstract
Stephens DM et al. Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925; NCT#04269902). ASH 2021;Abstract 2630.
Tam CS et al. SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2021;Abstract 396.
Wang E et al. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N Engl J Med 2022;386(8):735-43. Abstract
Wierda WG et al. Measurable residual disease in chronic lymphocytic leukemia: Expert review and consensus recommendations. Leukemia 2021;35(11):3059-72. Abstract
Woyach J et al. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 2021;62(13):3278-82. Abstract
Woyach JA et al. Long-term results of A041202 continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. ASH 2021;Abstract 639.